Aesthetic device company BTL Aesthetics has announced the launch of its EXOMIND device debuting at the Clinical Cosmetic Regenerative Congress (CCR).
The company describes EXOMIND as a non-invasive device, designed to support and improve mental wellbeing. By stimulating key areas of the brain linked to emotional regulation, cognitive function and self-control, EXOMIND aims to enhance neural connectivity and promote overall psychological wellness.
Zbyněk Pišťák, regional manager of BTL Aesthetics UK&I, Baltics & Finland and Jamaica & Malta, commented, “Around 50% of aesthetic patients experience challenges with their mental wellbeing. As a specialty, we’re beginning to recognise the connection between mental health and physical appearance, and the need to support both equally. While most treatments focus purely on the physical, EXOMIND offers a science-backed way to support emotional balance.”
